Double-blind active placebo-controlled phase 2 psilocybin-assisted psychotherapy for treatment-resistant chronic post-traumatic stress disorder

Phase 2, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing Psilocybin capsule + infusion placebo with Intravenous ketamine + placebo capsule (2 arms). Primary endpoint: Efficacy and safety of psilocybin-assisted psychotherapy in treatment-resistant chronic post-traumatic stress disorder. Planned start Jan 2025; status: not yet recruiting.